{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Study RA0010', 'Study RA0010 was a Phase I/IIa study to characterize the PK/PD relationship between', 'systemic OKZ exposure and CRP suppression, following single-dose IV and SC OKZ', 'administration to subjects with RA and to evaluate the safety and tolerability of single doses', 'of OKZ in RA subjects over a therapeutic dose range (as defined by CRP suppression).', 'Study RA0074', 'Study RA0074 was a Phase I study in healthy Japanese subjects undertaken to evaluate the', 'PK, PD, safety, and tolerability of SC OKZ prior to undertaking clinical studies in Japanese', 'subjects with RA.', 'Studies RA0056 and RA0057', 'Study RA0056 was a Phase II, multicenter, randomized, double-blind, placebo- and', 'active-controlled study of OKZ in 221 subjects in the United States (US) and Europe with', 'active RA who had previously failed TNFi therapy, administered SC at various doses and', 'frequencies to evaluate the efficacy relative to placebo. Eligible subjects were randomized to', '1 of 9 treatment groups: OKZ 60 mg SC once every 2 weeks (q2w), OKZ 60 mg SC once', 'every 4 weeks (q4w), OKZ 120 mg SC q2w, OKZ 120 mg SC q4w, OKZ 240 mg SC q2w,', 'OKZ 240 mg SC q4w, placebo SC q2w, placebo SC q4w, and tocilizumab 8 mg/kg IV q4w.', 'Study RA0057 was the long-term OLE study of RA0056, which was open for enrollment of', 'subjects who had completed the Week 12 visit of Study RA0056. A total of 190 subjects in', 'Study RA0057 received SC injections of OKZ 120 mg q2w throughout the study, regardless', 'of their treatment assignment in RA0056.', 'Studies RA0083 and RA0089', 'Study RA0083 was a Phase II, multicenter, randomized, double-blind, placebo-controlled,', 'dose-ranging study of OKZ in 119 Asian subjects with moderately to severely active RA who', 'had previously failed TNFi therapy and were on a stable dose of MTX. Eligible subjects', 'were randomized to 1 of 6 treatment groups: OKZ 60 mg q2w, 60 mg q4w, 120 mg q2w,', '120 mg q4w, 240 mg q4w, or placebo q2w, all administered SC.', 'Study RA0089 was the long-term OLE study of RA0083, which was open for enrollment of', 'subjects who had completed the Week 12 visit of Study RA0083. A total of 103 subjects in', 'Study RA0089 received SC injections of OKZ 120 mg q2w throughout the study, regardless', 'of their treatment assignment in Study RA0083.', 'Amendment 2: 06 March 2019', '26', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '2.2.3.2', 'Summary of Safety Data from Olokizumab Studies', 'Study RA0001', 'There were no deaths or serious adverse events (SAEs) reported during the study and no', 'subject discontinued the study as a result of an adverse event (AE). The overall incidence of', 'reatment-emergent adverse events (TEAEs) was slightly higher in the placebo group overall', '(18 subjects [52.9%]; 35 events) than in the OKZ treatment groups overall (11 subjects', '[33.3%]; 26 events). No increase in the incidence of TEAEs was observed with increasing', 'dose of OKZ.', 'The most commonly reported TEAEs were in the system organ classes (SOCs) of', 'gastrointestinal (GI) disorders, general disorders, and infections and infestations. The', 'incidence of GI disorders was similar in both the OKZ group overall (12.1%) and the placebo', 'group overall (11.8%); however, at the preferred term (PT) level, abdominal distension', '(1 subject [3.0%]), abdominal pain (1 subject [3.0%]), and vomiting (2 subjects [6.1%]) were', 'only seen in the OKZ group. The most frequently reported TEAEs (occurring in 3% of', 'subjects in any treatment group) by PT were influenza-like illness (11.8% placebo,', '6.1% OKZ), headache (11.8% placebo, 3.0% OKZ), nasopharyngitis (8.8% placebo,', '3.0% OKZ), rhinitis (8.8% placebo, 0.0% OKZ), diarrhea (5.9% placebo, 3.0% OKZ), and', 'vomiting (0.0% placebo, 6.1% OKZ).', 'For the majority of hematology and clinical chemistry parameters there were no clinically', 'significant differences in mean actual values between the placebo group and OKZ treatment', 'groups, and no clinically significant fluctuations in mean actual values over time.', 'Study RA0010', 'There were no deaths during Study RA0010. Two subjects (1 subject in the placebo', 'IV + MTX group and 1 subject in the OKZ 1 mg/kg SC + MTX group) experienced SAEs:', \"Bowen's disease and worsening of RA, respectively. Neither event was considered by the\", 'Investigator to be related to the study treatment. One subject in the placebo + MTX overall', 'group withdrew from the study as a result of exacerbation of their RA. All subjects (100%)', 'in the placebo + MTX overall group and 96.7% of subjects in the OKZ + MTX overall group', 'experienced at least 1 TEAE. The incidence of TEAEs did not increase with increasing dose', 'of OKZ + MTX administered; although, a slightly higher number of AEs were experienced', 'by subjects in the OKZ (1 mg/kg and 3 mg/kg) + MTX SC treatment groups', '(16 subjects [94.12%]; 101 events) compared with the OKZ (0.1 mg/kg and 1 mg/kg) + MTX', 'IV treatment groups (13 subjects [100%]; 54 events).', 'Amendment 2: 06 March 2019', '27', 'Confidential']\n\n###\n\n", "completion": "END"}